ArticleJournal of psychiatry and brain science2019
Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism.
Article in Journal of psychiatry and brain science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Sex-specific effects of the atypical antipsychotic risperidone on performance in a risky decision-making task.Behavioural brain research · 2027Article
- Fenofibrate Protects Against Antipsychotic-Induced Hyperglycemia Through Weight Loss and FGF21 Dependent Mechanisms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Identifying genetic contributions of 6q21 loci and PPAR pathway to antipsychotic-induced metabolic syndrome: a Sex-Stratified Multi-Omics study.Molecular psychiatry · 2026Article
- Effectiveness of a Psychiatrist-Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study.Acta psychiatrica Scandinavica · 2026Article
- Effects of antipsychotics on brain insulin action in females: Study protocol for a placebo-controlled, crossover neuroimaging study.PloS one · 2026Article
- Risk Factors and Management Strategies for Antipsychotic-Induced Weight Gain: A Prescriptive Review for Clinicians.Focus (American Psychiatric Publishing) · 2025Review
- Age and sex differences in outpatient antipsychotic prescriptions for schizophrenia: a claims data study.European archives of psychiatry and clinical neuroscience · 2025Article
- Reutericyclin mitigates risperidone-induced suppression of anaerobic energy expenditure.American journal of physiology. Regulatory, integrative and comparative physiology · 2025Article
- GLP-2 attenuates antipsychotics' adverse metabolic effects.Nature metabolism · 2025Article
- Peripheral Lipid Signatures, Metabolic Dysfunction, and Pathophysiology in Schizophrenia Spectrum Disorders.Metabolites · 2024Review
- Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model.CNS neuroscience & therapeutics · 2024Article
- Amylin receptor agonism enhances the effects of liraglutide in protecting against the acute metabolic side effects of olanzapine.iScience · 2024Article
- Long-acting antipsychotic treatments: focus on women with schizophrenia.Therapeutic advances in psychopharmacology · 2024Review
- Epigenetic Histone Methylation of PPARγ and CPT1A Signaling Contributes to Betahistine Preventing Olanzapine-Induced Dyslipidemia.International journal of molecular sciences · 2023Article
- Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism.Frontiers in pharmacology · 2023Article
- Implications of Dietary Intake and Eating Behaviors for People with Serious Mental Illness: A Qualitative Study.Nutrients · 2022Article
- The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice.Diabetologia · 2022Article
- Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review.Therapeutic advances in psychopharmacology · 2022Article
- Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance.Frontiers in pharmacology · 2022Article
- Estrogens in schizophrenia: progress, current challenges and opportunities.Current opinion in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Antipsychotic (AP) medications are associated with an increased risk of developing metabolic side effects including weight gain, type 2 diabetes (T2D), dyslipidemia, and hypertension. In the majority of clinical studies, females on APs are noted to gain more weight, and are more likely to be diagnosed with metabolic syndrome when compared to males. However, the data is less clear when comparing sex disparities associated with other specific AP-induced metabolic risk factors. Accumulating evidence has demonstrated a role for AP-induced adipose tissue accumulation as well as whole body glucose dysregulation in male models that is independent of changes in body weight. The purpose of this narrative review is to explore the susceptibility of males and females to changes in adiposity and glucose metabolism across clinical and preclinical models of AP treatment. It is important that future research examining AP-induced metabolic side effects analyzes outcomes by sex to help clarify risk and identify the mechanisms of adverse event development to improve safe prescribing of medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.